Case Review Form

      * Denotes required field.

      Title

      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address

      Apartment/Suite

      City

      State

      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person
      (mm-dd-yyyy):

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

Jury Selection Begins in First Actos Trial

Filed February 20th, 2013 admin

Jury selection began in Los Angeles state court, Tuesday, in the first of 3,000 Actos lawsuits to go to trial.

The lawsuit is being brought by Jack Cooper, who alleges that Takeda’s diabetes medication, Actos, caused him to develop bladder cancer. The lawsuit claims that Takeda failed to properly warn Cooper or the public about the risks of taking Actos even though they were aware that it could cause bladder cancer prior to approval. Cooper alleges that Takeda turned down the U.S. Food & Drug Administration’s (FDA) request to add a bladder cancer warning to the Actos label for years. in an effort to increase sales. Actos was once the best-selling diabetes drug in the world, with sales peaking in March 2011 at $4.5 billion, which accounted for 27 percent of Takeda’s revenue at the time.

Actos, which is part of the thiazolidinedione class, was approved in 1999 to treat patients with Type 2 diabetes. The thiazolidinedione class also includes the medication Avandia. Sales of Actos have fallen drastically in recent years after multiple studies connected the use of Actos to bladder, kidney and liver cancer. In June 2011, the drug was pulled off the shelves in France and Germany due to its association with bladder cancer. Meanwhile, the FDA has warned that taking Actos for more than a year could greatly raise the risk of developing bladder cancer.

Many of the 3,000 cases against Takeda are pending in a multidistrict litigation (MDL). In addition to cancer, Actos has been linked to heart attacks, congestive heart failure, edema and hepatitis.

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!